[go: up one dir, main page]

AR100820A1 - Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas - Google Patents

Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas

Info

Publication number
AR100820A1
AR100820A1 ARP150101871A ARP150101871A AR100820A1 AR 100820 A1 AR100820 A1 AR 100820A1 AR P150101871 A ARP150101871 A AR P150101871A AR P150101871 A ARP150101871 A AR P150101871A AR 100820 A1 AR100820 A1 AR 100820A1
Authority
AR
Argentina
Prior art keywords
formulations
layer
capecitabine
cyclofosphamide
fractioned
Prior art date
Application number
ARP150101871A
Other languages
English (en)
Original Assignee
Sanofi-Synthelabo (India) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo (India) Ltd filed Critical Sanofi-Synthelabo (India) Ltd
Publication of AR100820A1 publication Critical patent/AR100820A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación de comprimido oral bi-capa de ciclofosfamida y capecitabina y métodos de preparación de estas formulaciones. Además, dichas formulaciones son útiles para administración metronómica para tratar cáncer, por ejemplo, cáncer de mama. Reivindicación 4: La formulación de comprimido de una cualquiera de las reivindicaciones 1 a 3, en la que el único comprimido bi-capa está recubierto con película. Reivindicación 7: La formulación de comprimido de la reivindicación 6, en la que el recubrimiento con película aplicado comprende la composición siguiente: @@@@@@@@@
ARP150101871A 2014-06-12 2015-06-11 Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas AR100820A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1596DE2014 2014-06-12

Publications (1)

Publication Number Publication Date
AR100820A1 true AR100820A1 (es) 2016-11-02

Family

ID=53724388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101871A AR100820A1 (es) 2014-06-12 2015-06-11 Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas

Country Status (3)

Country Link
AR (1) AR100820A1 (es)
TW (1) TW201613563A (es)
WO (1) WO2015189807A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018072583A2 (pt) * 2016-05-03 2019-02-19 Intas Pharmaceuticals Ltd composição farmacêutica de comprimido em comprimido estável

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
US20140309183A1 (en) * 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
IN2013MU03118A (es) * 2013-09-30 2015-08-14 Intas Pharmaceuticals Ltd

Also Published As

Publication number Publication date
WO2015189807A1 (en) 2015-12-17
TW201613563A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO2018008207A2 (es) Composiciones para el cuidado bucal y métodos para utilizar las composiciones
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MX2019010322A (es) Composiciones farmaceuticas para el tratamiento combinado.
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
PH12016502386A1 (en) Oral care compositions
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
AR100820A1 (es) Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas
MX2017004909A (es) Composiciones de triptamina y metodos de uso.
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2019015869A (es) Nuevas formulaciones orales de belinostat.

Legal Events

Date Code Title Description
FB Suspension of granting procedure